Search | Clinical Trials Finder

Conditions: Anal, Colon, and Rectal Cancers, Head and Neck Cancer, Lung Cancer, Colon Cancer, Colonic Neoplasms, Colorectal Neoplasms, Colon/Rectal Cancer, Colon/Rectal Cancer Colon Cancer, Colon/Rectal Cancer Rectal Cancer, Colon/Rectal Cancer Anal Cancer, Head and Neck Cancers, Head and Neck Cancers Lip, Head and Neck Cancers Oral Cavity, Head and Neck Cancers Nasopharynx, Head and Neck Cancers Oropharynx, Head and Neck Cancers Hypopharynx, Head and Neck Cancers Larynx, Head and Neck Cancers Trachea, Lung Cancer Non-Small Cell Cancer (NSCLC), Lung Cancer Small Cell Lung Cancer (SCLC)
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Stanford, California

Conditions: TNBC - Triple-Negative Breast Cancer, Triple Negative Breast Cancer, NSCLC, NSCLC Stage IV, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, NSCLC Stage IV Without EGFR/ALK Mutation
Interventions: Sterotactic Body Radiotherapy/SBRT, Standard of care; Radiation · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 9
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 6 more

Conditions: Non Small Cell Lung Cancer
Interventions: Telisotuzumab Vedotin, Docetaxel; Biological · Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 768 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 50
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 46 more

Conditions: Advanced Solid Tumor
Interventions: DB-1310, Trastuzumab, Osimertinib, capecitabine; Drug
Lead sponsor: DualityBio Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 15
States / cities: Sacramento, California • Santa Monica, California • Coral Gables, Florida + 12 more

Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
Interventions: Cetuximab, Paclitaxel, Carboplatin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 14
States / cities: Little Rock, Arkansas • Long Beach, California • Boynton Beach, Florida + 11 more

Conditions: NSCLC
Interventions: Aliya Pulsed Electric Fields (PEF) ablation, Nivolumab plus Platinum Doublet Chemotherapy, Standard of care neoadjuvant therapy, Surgical Resection; Device · Drug · Other
Lead sponsor: Galvanize Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Rochester, Minnesota • Philadelphia, Pennsylvania

Conditions: Advanced Solid Tumors, Colorectal Cancer, Squamous Cell Head and Neck Cancer, Non Small Cell Lung Cancer, Triple Negative Breast Cancer
Interventions: MM-151, MM-151 + irinotecan; Drug
Lead sponsor: Merrimack Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 4
States / cities: Aurora, Colorado • Lafayette, Indiana • Buffalo, New York + 1 more

Conditions: Non Small Cell Lung Carcinoma
Interventions: AZD6244, Erlotinib, AZD6244 + Erlotinib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 5
States / cities: Davis, California • Los Angeles, California • South Pasadena, California + 2 more

Conditions: ALK Gene Mutation, BRAF Gene Mutation, EGFR Gene Mutation, Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, ROS1 Gene Mutation, Stage III Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions: Laboratory Biomarker Analysis, Pembrolizumab, Recombinant EphB4-HSA Fusion Protein; Other · Biological
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Non-Small Cell Lung Cancer
Interventions: PF-06747775, Palbociclib, Avelumab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 7
States / cities: La Jolla, California • San Diego, California • New Haven, Connecticut + 2 more

Conditions: Non - Small Cell Lung Cancer NSCLC
Interventions: MEDI4736 (durvalumab), Vinorelbine, Gemcitabine, Erlotinib, MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4), tremelimumab (anti-CTLA4); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 597 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 33
States / cities: Chandler, Arizona • Anaheim, California • Duarte, California + 29 more

Conditions: Advanced Solid Tumors Cancer
Interventions: ABBV-321; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 14
States / cities: Springdale, Arkansas • Los Angeles, California • Sacramento, California + 10 more

Conditions: Non-small Cell Lung Cancer
Interventions: erlotinib, hydroxychloroquine; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: NSCLC
Interventions: Poziotinib, Docetaxel; Drug
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 268 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Winter Haven, Florida

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Savolitinib, Osimertinib, Pemetrexed, Cisplatin, Carboplatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 341 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 5
States / cities: Orlando, Florida • Honolulu, Hawaii • New Brunswick, New Jersey + 2 more

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: Osimertinib, SABR; Drug · Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 2
States / cities: Duarte, California • Dallas, Texas

Conditions: EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
Interventions: AZD3759, AZD9291; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 2
States / cities: Los Angeles, California • Santa Monica, California

Conditions: Non Small Cell Lung Cancer
Interventions: Pharmacokinetic sampling - AZD9291, Simvastatin, AZD9291 tablet dosing, Pharmacokinetic sampling - simvastatin, Pharmacokinetic sampling - AZ5140 and AZ7550; Procedure · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer
Interventions: AZD9291; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 603 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 7
States / cities: Aurora, Colorado • Atlanta, Georgia • Boston, Massachusetts + 3 more

Conditions: Non-Small Cell Lung Cancer
Interventions: PET-Adaptive RT, Erlotinib, Crizotinib; Radiation · Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2015
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Lung Cancer, Non Small Cell Lung Cancer
Interventions: Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined); Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Duarte, California • Aurora, Colorado • Ann Arbor, Michigan

Conditions: Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Aurora A Kinase Inhibitor LY3295668, Osimertinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lung Adenocarcinoma, Lung Neoplasms
Interventions: osimertinib, Local Ablative Therapy (LAT); Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Non-Small Cell Lung Cancer
Interventions: Durvalumab, Danvatirsen, Ceralasertib, Vistusertib, Olaparib, Oleclumab, Trastuzumab deruxtecan, Cediranib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 528 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 17
States / cities: Duarte, California • Fullerton, California • La Jolla, California + 12 more

Search by objective public record fields.

Clinical and Pathologic Studies of Patients Undergoing Treatment With EGFR Inhibitors

Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and Paclitaxel

Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC

Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment

Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...

Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475

Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)

A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)

Hydroxychloroquine With or Without Erlotinib in Advanced Non-small Cell Lung Cancer (NSCLC)

A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC

Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer

Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC

AZD9291 First Time In Patients Ascending Dose Study

Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations

Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations

Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer

Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib

Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy